Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — IgG4-related disease may be regarded as this century’s “greatest mimicker,” but upcoming ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Uplizna met all primary and secondary endpoints for ...

Inebilizumab-cdon, a monoclonal antibody that depletes B cells, reduces the risk for flares without showing any new safety signals in patients with immunoglobulin G4-related disease (IgG4-RD) who have ...

Advances Amgen (AMGN)'s Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ -- ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD). An international, ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of patients ...

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the therapeutic indication of Uplizna (inebilizumab, Amgen Europe) to include ...

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen’s latest clinical move targets a niche but ...

DelveInsight’s “IgG4-related Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the IgG4-related Disease, historical and forecasted ...

Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG IgG4-RD can occur in multiple organs and lead to fibrosis and ...